期刊
LIFE-BASEL
卷 12, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/life12030460
关键词
Alzheimer's disease; anti-dementia drugs; biomarkers; cerebrovascular genomics; concomitant disorders; neurodegenerative genomics; pathogenic genes; phenotype-modifying treatments; pharmacogenomics
资金
- EuroEspes, S.A.
- IABRA (International Agency for Brain Research and Aging)
Alzheimer's disease is a significant health problem with high societal cost and resource consumption. Managing patients with AD is complex and requires multidisciplinary approach. Personalized therapeutic regimens are necessary due to concomitant diseases and the need to reduce adverse drug reactions, drug-drug interactions, and unnecessary costs. Predictive and differential diagnosis can be aided by genomic, epigenetic, neuroimaging, and biochemical biomarkers.
Alzheimer's disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources. The management of AD patients is complex and multidisciplinary. Over 90% of patients suffer from concomitant diseases and require personalized therapeutic regimens to reduce adverse drug reactions (ADRs), drug-drug interactions (DDIs), and unnecessary costs. Men and women show substantial differences in their AD-related phenotypes. Genomic, epigenetic, neuroimaging, and biochemical biomarkers are useful for predictive and differential diagnosis. The most frequent concomitant diseases include hypertension (>25%), obesity (>70%), diabetes mellitus type 2 (>25%), hypercholesterolemia (40%), hypertriglyceridemia (20%), metabolic syndrome (20%), hepatobiliary disorder (15%), endocrine/metabolic disorders (>20%), cardiovascular disorder (40%), cerebrovascular disorder (60-90%), neuropsychiatric disorders (60-90%), and cancer (10%). Over 90% of AD patients require multifactorial treatments with risk of ADRs and DDIs. The implementation of pharmacogenetics in clinical practice can help optimize the limited therapeutic resources available to treat AD and personalize the use of anti-dementia drugs, in combination with other medications, for the treatment of concomitant disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据